丰倍生物
(603334)
| 流通市值：15.56亿 | | | 总市值：71.91亿 |
| 流通股本：3105.36万 | | | 总股本：1.44亿 |
| 报告期 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 567,157,391.04 | 106,015,042.8 | 202,085,702.7 | 166,784,851.31 |
| 交易性金融资产 | 300,141,723.04 | 13,362.68 | 16,839.87 | - |
| 应收票据及应收账款 | 231,827,513.88 | 243,768,031.67 | 262,348,817.72 | 196,068,220.38 |
| 其中：应收票据 | 59,241,556.25 | 45,277,000.85 | 83,148,249.79 | 62,908,474.57 |
| 应收账款 | 172,585,957.63 | 198,491,030.82 | 179,200,567.93 | 133,159,745.81 |
| 应收款项融资 | 12,862,336.23 | 46,494,218.31 | 61,241,938.43 | 43,283,726.14 |
| 预付款项 | 43,911,971.98 | 127,026,269.05 | 54,659,349.94 | 34,488,568.71 |
| 其他应收款合计 | 12,366,438.25 | 12,154,892.73 | 20,758,096.69 | 14,657,028.35 |
| 存货 | 522,601,983.74 | 368,414,843.94 | 255,014,122.6 | 242,006,506.14 |
| 合同资产 | 4,505,898.61 | 6,385,212.41 | 6,352,712.41 | 5,472,745.6 |
| 其他流动资产 | 31,907,618.43 | 27,210,483.54 | 19,944,429.33 | 27,414,557.86 |
| 流动资产合计 | 1,727,282,875.2 | 937,482,357.13 | 882,422,009.69 | 730,176,204.49 |
| 非流动资产: | | | | |
| 固定资产 | 389,868,420.82 | 277,191,036.76 | 283,523,151.95 | 134,247,696.92 |
| 在建工程 | 25,201,303.41 | 142,734,084.23 | 140,506,086.77 | 291,805,362.6 |
| 使用权资产 | 1,811,863.71 | 4,613,148.77 | 5,399,112.02 | 6,971,038.52 |
| 无形资产 | 63,066,364.5 | 58,440,401.35 | 59,073,142.14 | 59,762,958.48 |
| 商誉 | 17,176.8 | - | - | - |
| 长期待摊费用 | 1,622,014.62 | 1,615,481.98 | 1,888,336.32 | 2,607,089.13 |
| 递延所得税资产 | 11,655,955.77 | 9,984,853.76 | 9,362,172.36 | 8,858,497.68 |
| 其他非流动资产 | 4,818,356.73 | 3,793,127.39 | 2,048,394.38 | 2,326,655.97 |
| 非流动资产合计 | 498,061,456.36 | 498,372,134.24 | 501,800,395.94 | 506,579,299.3 |
| 资产总计 | 2,225,344,331.56 | 1,435,854,491.37 | 1,384,222,405.63 | 1,236,755,503.79 |
| 流动负债: | | | | |
| 短期借款 | 222,713,829.84 | 259,605,336.08 | 235,126,578.87 | 173,391,290.74 |
| 交易性金融负债 | 258,500.64 | 185,451.24 | 154,952.69 | 363,959.57 |
| 应付票据及应付账款 | 168,292,594.69 | 139,141,288 | 132,155,056.04 | 113,111,252.45 |
| 其中：应付票据 | 55,314,977.51 | 64,392,425.86 | 47,620,057.95 | 37,812,830.6 |
| 应付账款 | 112,977,617.18 | 74,748,862.14 | 84,534,998.09 | 75,298,421.85 |
| 合同负债 | 51,076,712.73 | 10,616,235.32 | 4,099,984.58 | 27,438,888.17 |
| 应付职工薪酬 | 14,760,653.11 | 9,755,459.17 | 7,704,205.64 | 11,174,750.52 |
| 应交税费 | 19,080,417.25 | 13,333,501.01 | 23,047,177.52 | 8,937,576 |
| 其他应付款合计 | 1,941,071.68 | 2,068,123.76 | 2,042,468.28 | 1,860,202.24 |
| 一年内到期的非流动负债 | 6,141,964.32 | 30,608,598.96 | 10,987,815.31 | 10,374,187.62 |
| 其他流动负债 | 7,550,145.16 | 2,024,740.29 | 12,176,557.3 | 11,882,713.22 |
| 流动负债合计 | 491,815,889.42 | 467,338,733.83 | 427,494,796.23 | 358,534,820.53 |
| 非流动负债: | | | | |
| 长期借款 | 22,440,000 | 80,190,000 | 100,640,000 | 106,370,000 |
| 租赁负债 | 486,059 | 1,420,164.47 | 1,902,400.32 | 3,481,960.65 |
| 递延收益 | 10,484,706.38 | 10,789,044.79 | 11,003,905.48 | 11,355,372.51 |
| 递延所得税负债 | 372,843.26 | 1,144,745.9 | 1,072,183.31 | 1,221,866.77 |
| 非流动负债合计 | 33,783,608.64 | 93,543,955.16 | 114,618,489.11 | 122,429,199.93 |
| 负债合计 | 525,599,498.06 | 560,882,688.99 | 542,113,285.34 | 480,964,020.46 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 143,500,000 | 107,600,000 | 107,600,000 | 107,600,000 |
| 资本公积 | 955,240,999.94 | 191,590,089.5 | 190,962,925.31 | 189,708,596.93 |
| 盈余公积 | 37,647,819.58 | 26,948,993.72 | 26,948,993.72 | 26,948,993.72 |
| 未分配利润 | 561,389,690.74 | 548,832,719.16 | 516,597,201.26 | 431,533,892.68 |
| 归属于母公司股东权益合计 | 1,697,778,510.26 | 874,971,802.38 | 842,109,120.29 | 755,791,483.33 |
| 少数股东权益 | 1,966,323.24 | - | - | - |
| 股东权益合计 | 1,699,744,833.5 | 874,971,802.38 | 842,109,120.29 | 755,791,483.33 |
| 负债和股东权益合计 | 2,225,344,331.56 | 1,435,854,491.37 | 1,384,222,405.63 | 1,236,755,503.79 |
| 公告日期 | 2026-04-10 | 2025-11-04 | 2025-08-15 | 2025-06-30 |
| 审计意见(境内) | 标准无保留意见 | | 标准无保留意见 | 标准无保留意见 |